Taribavirin in the treatment of hepatitis C. - Wikidata - wikimedia - TriplyDB

Taribavirin in the treatment of hepatitis C.

Taribavirin in the treatment of hepatitis C.

http://www.wikidata.org/entity/Q37919889

about

Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).

P2860

Q39079255-A77533A0-9C33-4F5B-AA64-68383D696BB4

P2860

Taribavirin in the treatment of hepatitis C.

http://www.wikidata.org/entity/Q37919889

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Taribavirin in the treatment of hepatitis C.

@en

Taribavirin in the treatment of hepatitis C.

@nl

type

label

Taribavirin in the treatment of hepatitis C.

@en

Taribavirin in the treatment of hepatitis C.

@nl

prefLabel

Taribavirin in the treatment of hepatitis C.

@en

Taribavirin in the treatment of hepatitis C.

@nl

P1433

Q37919889-668328F6-A585-4CD4-A951-6E73DDDF2D3E

P1476

Q37919889-52F662C6-1BE2-4D94-AE93-414787D7B70E

P2093

Q37919889-1A7EF33F-232B-453A-B3B1-AD1E6F99EF80

Q37919889-752A9B19-C5E4-4D65-9B27-71A01DB4D18B

P2860

Q37919889-13A72CC1-E91B-4285-AD60-4987903A0E08

Q37919889-15DB2A80-A54F-4263-8C3F-EA0BE526B1EA

Q37919889-164F3749-8B49-49E4-B6DA-B1AD6C63C3C4

Q37919889-1C38CD99-3A8D-430F-8B21-8DA28EC44170

Q37919889-25B8393E-AA0B-46C9-80E9-048D58A630F0

Q37919889-27D8DFD3-E0E7-4882-9523-A74BB0F3EF3D

Q37919889-404BF24C-2306-4AC1-99DC-33AF08225B65

Q37919889-455F182A-0B44-4F77-8BD8-27BD40B794FA

Q37919889-4E584E62-D8C2-4C9C-9812-30F825B80E3B

Q37919889-508DF407-0F47-469D-941B-5E689093F9C3

P304

Q37919889-EB68416B-2E6C-4E3F-B805-9027FB96DE92

P31

Q37919889-E7A7E444-267D-4D8A-8A87-4F7FDBC34C16

P356

Q37919889-8F88AE75-C6FD-4130-999E-3C16CF17387F

P407

Q37919889-C8290C93-AB0A-44B5-B52C-CBDA5E5A5B2A

P433

Q37919889-9A2187EE-4AF4-4737-AE69-0CBF9D01A4BB

P478

Q37919889-D6196F77-BA1F-4E92-A4E7-8FA5FB7B2D9A

P50

Q37919889-F6C1EA9E-A077-4BD7-BBC4-809A465CE001

P577

Q37919889-39F2F89E-3D0D-4AB4-82F4-DCB0177AA5C8

P698

Q37919889-AFDF474D-4147-4B61-A201-1B77D467CCE2

P356

13543784.2011.606214

P1433

Expert Opinion on Investigational Drugs

P1476

Taribavirin in the treatment of hepatitis C.

@en

P2093

Paulina Deming

http://www.w3.org/2001/XMLSchema#string

Sanjeev Arora

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys

Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C

Treating HCV with ribavirin analogues and ribavirin-like molecules

The global burden of hepatitis C

Role of epoetin alfa in maintaining ribavirin dose.

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.

Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design.

Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences.

Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.

P304

1435-1443

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2011.606214

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21854301

http://www.w3.org/2001/XMLSchema#string